SEPE, PIERANGELA
SEPE, PIERANGELA
Universita' degli Studi di MILANO
Outpatient palliative care referral system (PCRS) for patients with advanced cancer: an impact evaluation protocol
2024 C. Brunelli, E. Zecca, A. Pigni, P. Bracchi, M. Caputo, S. Lo Dico, V. Fusetti, A. Tallarita, C. Bergamini, M. Brambilla, A. Raimondi, M. Niger, S. Provenzano, P. Sepe, S. Alfieri, G. Tinè, F. De Braud, A.T. Caraceni
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)
2022 A. Mennitto, E. Zattarin, M. Di Maio, D. Bimbatti, U. De Giorgi, S. Buti, D. Santini, C. Casadei, M. Soraru, C. Messina, C. Mucciarini, G. Di Lorenzo, G. Roviello, C. Buttigliero, M. Stellato, P. Sepe, M. Claps, V. Guadalupi, A. Ottini, S. Pignata, F.G. De Braud, E. Verzoni, G. Procopio
Biomarker-driven immunotherapy for precision medicine in prostate cancer
2022 A. Ottini, P. Sepe, T. Beninato, M. Claps, V. Guadalupi, E. Verzoni, P. Giannatempo, G. Baciarello, F. De Braud, G. Procopio
Integrative transcriptomic analysis reveals distinctive molecular traits and novel subtypes of collecting duct carcinoma
2021 C. Gargiuli, P. Sepe, A. Tessari, T. Sheetz, M. Colecchia, F.G.M. de Braud, G. Procopio, M. Sensi, E. Verzoni, M. Dugo
Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma
2021 R. Ratta, E. Verzoni, A. Mennitto, F. Pantano, A. Martinetti, A. Raimondi, P. Sepe, E. Sottotetti, R. Mennitto, D. Morelli, D. Santini, F. de Braud, G. Procopio
Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer
2020 C. Vernieri, M. Prisciandaro, F. Nichetti, R. Lobefaro, G. Peverelli, F. Ligorio, E. Zattarin, M.S. Cona, P. Sepe, F. Corti, S. Manglaviti, M. Brambilla, B. Re, A. Belfiore, G. Pruneri, L. Celio, G. Mariani, G.V. Bianchi, L. Rivoltini, G. Capri, F. de Braud
Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis
2020 R. Lobefaro, E. Zattarin, F. Nichetti, M. Prisciandaro, F. Ligorio, M. Brambilla, P. Sepe, F. Corti, G. Peverelli, A. Ottini, T. Beninato, L. Mazzeo, C.G. Rea, G. Mariani, F. de Braud, G.V. Bianchi, C. Vernieri, G. Capri